JP2011519832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519832A5 JP2011519832A5 JP2011505549A JP2011505549A JP2011519832A5 JP 2011519832 A5 JP2011519832 A5 JP 2011519832A5 JP 2011505549 A JP2011505549 A JP 2011505549A JP 2011505549 A JP2011505549 A JP 2011505549A JP 2011519832 A5 JP2011519832 A5 JP 2011519832A5
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- benzamide
- phenyl
- amino
- thioxomethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VKPLPDIMEREJJF-UHFFFAOYSA-N 3-methoxybenzamide Chemical compound COC1=CC=CC(C(N)=O)=C1 VKPLPDIMEREJJF-UHFFFAOYSA-N 0.000 claims 144
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 111
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 109
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 58
- -1 polycyclic hydrocarbon Chemical class 0.000 claims 52
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical group O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 12
- VHBTUNPEVBMRRY-UHFFFAOYSA-N n-[[3-(1h-benzimidazol-2-yl)-4-methylphenyl]carbamothioyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(C(C)=CC=2)C=2NC3=CC=CC=C3N=2)=C1 VHBTUNPEVBMRRY-UHFFFAOYSA-N 0.000 claims 12
- FJNOMPZPFBXDRQ-UHFFFAOYSA-N 3,4,5-trimethoxy-n-[[3-[(4-phenylphenyl)carbamoylamino]phenyl]carbamothioyl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(NC(=O)NC=3C=CC(=CC=3)C=3C=CC=CC=3)C=CC=2)=C1 FJNOMPZPFBXDRQ-UHFFFAOYSA-N 0.000 claims 10
- 125000002950 monocyclic group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000003367 polycyclic group Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000004434 sulfur atom Chemical group 0.000 claims 5
- 230000003902 lesion Effects 0.000 claims 4
- 230000000626 neurodegenerative effect Effects 0.000 claims 4
- 125000002560 nitrile group Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 239000004215 Carbon black (E152) Substances 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229930195733 hydrocarbon Natural products 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 claims 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 claims 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 claims 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 claims 2
- GUCPYIYFQVTFSI-UHFFFAOYSA-N 4-methoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C=C1 GUCPYIYFQVTFSI-UHFFFAOYSA-N 0.000 claims 2
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 102000003693 Hedgehog Proteins Human genes 0.000 claims 2
- 108090000031 Hedgehog Proteins Proteins 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 claims 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 229940125782 compound 2 Drugs 0.000 claims 2
- 229940125810 compound 20 Drugs 0.000 claims 2
- 229940126086 compound 21 Drugs 0.000 claims 2
- 229940125833 compound 23 Drugs 0.000 claims 2
- 229940125961 compound 24 Drugs 0.000 claims 2
- 229940125846 compound 25 Drugs 0.000 claims 2
- 229940126214 compound 3 Drugs 0.000 claims 2
- 229940127573 compound 38 Drugs 0.000 claims 2
- 229940126545 compound 53 Drugs 0.000 claims 2
- 229940127113 compound 57 Drugs 0.000 claims 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- PHDSFVUKDSNSNP-UHFFFAOYSA-N n-[(3-imidazo[2,1-b][1,3]thiazol-6-ylphenyl)carbamothioyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(C=CC=2)C=2N=C3SC=CN3C=2)=C1 PHDSFVUKDSNSNP-UHFFFAOYSA-N 0.000 claims 2
- ZVRZMUZDUOXELB-UHFFFAOYSA-N n-[(3-indol-1-ylphenyl)carbamothioyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(C=CC=2)N2C3=CC=CC=C3C=C2)=C1 ZVRZMUZDUOXELB-UHFFFAOYSA-N 0.000 claims 2
- GGOOHMAHPJYVCU-UHFFFAOYSA-N n-[[3-(1h-indol-2-yl)phenyl]carbamothioyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(C=CC=2)C=2NC3=CC=CC=C3C=2)=C1 GGOOHMAHPJYVCU-UHFFFAOYSA-N 0.000 claims 2
- BGBLJBWRWCHKMK-UHFFFAOYSA-N n-[[3-(1h-indol-2-yl)phenyl]carbamoyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=O)NC=2C=C(C=CC=2)C=2NC3=CC=CC=C3C=2)=C1 BGBLJBWRWCHKMK-UHFFFAOYSA-N 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 claims 2
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 claims 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 claims 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 claims 1
- ZIBGOHCSAABMHS-UHFFFAOYSA-N 3,4,5-trimethoxy-n-[[3-[(4-phenylphenyl)carbamoylamino]phenyl]carbamoyl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=O)NC=2C=C(NC(=O)NC=3C=CC(=CC=3)C=3C=CC=CC=3)C=CC=2)=C1 ZIBGOHCSAABMHS-UHFFFAOYSA-N 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229940126657 Compound 17 Drugs 0.000 claims 1
- 229940127007 Compound 39 Drugs 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229940125877 compound 31 Drugs 0.000 claims 1
- 229940125900 compound 59 Drugs 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- DWAVRWHGZVNIKQ-UHFFFAOYSA-N n-[(3-imidazo[1,2-a]pyridin-2-ylphenyl)carbamothioyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC(=S)NC=2C=C(C=CC=2)C=2N=C3C=CC=CN3C=2)=C1 DWAVRWHGZVNIKQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 0 COc(cc(cc1OC)C(NC(Nc2cc(NC(c3ccccc3Cl)=O)ccc2)=S)=O)c1O* Chemical compound COc(cc(cc1OC)C(NC(Nc2cc(NC(c3ccccc3Cl)=O)ccc2)=S)=O)c1O* 0.000 description 4
- BFNOESVEKMASAA-UHFFFAOYSA-N CCOc(cc(cc1OCC)C(NC(Nc2cccc(NC(c3ccccc3)=O)c2)=S)=O)c1OCC Chemical compound CCOc(cc(cc1OCC)C(NC(Nc2cccc(NC(c3ccccc3)=O)c2)=S)=O)c1OCC BFNOESVEKMASAA-UHFFFAOYSA-N 0.000 description 2
- AZRGRNJRWFLKBH-UHFFFAOYSA-N COc(cc1)cc(OC)c1C(NC(Nc1cc(NC(c2ccccc2)=O)ccc1)=S)=O Chemical compound COc(cc1)cc(OC)c1C(NC(Nc1cc(NC(c2ccccc2)=O)ccc1)=S)=O AZRGRNJRWFLKBH-UHFFFAOYSA-N 0.000 description 2
- SDFCPIHDTKKVJX-UHFFFAOYSA-N COc1cc(C(NC(Nc2cccc(NC(Nc3ccccc3)=O)c2)=S)=O)cc(OC)c1OC Chemical compound COc1cc(C(NC(Nc2cccc(NC(Nc3ccccc3)=O)c2)=S)=O)cc(OC)c1OC SDFCPIHDTKKVJX-UHFFFAOYSA-N 0.000 description 2
- XNXPHKVTUGIUIP-UHFFFAOYSA-N COc(cc(cc1OC)C(NC(Nc(cc2)cc(C(Nc3ccccc3)=O)c2Cl)=S)=O)c1OC Chemical compound COc(cc(cc1OC)C(NC(Nc(cc2)cc(C(Nc3ccccc3)=O)c2Cl)=S)=O)c1OC XNXPHKVTUGIUIP-UHFFFAOYSA-N 0.000 description 1
- HSYJXXQMBVDCDP-UHFFFAOYSA-N COc(cc(cc1OC)C(NC(Nc(cc2)cc(NC(c3ccccc3)=O)c2Cl)=S)=O)c1OC Chemical compound COc(cc(cc1OC)C(NC(Nc(cc2)cc(NC(c3ccccc3)=O)c2Cl)=S)=O)c1OC HSYJXXQMBVDCDP-UHFFFAOYSA-N 0.000 description 1
- NQAUEOAYCLBHRR-UHFFFAOYSA-N Cc(ccc(NC(NC(c(cc1OC)cc(OC)c1OC)=O)=S)c1)c1NC(c1ccccc1)=O Chemical compound Cc(ccc(NC(NC(c(cc1OC)cc(OC)c1OC)=O)=S)c1)c1NC(c1ccccc1)=O NQAUEOAYCLBHRR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0802302A FR2930552B1 (fr) | 2008-04-24 | 2008-04-24 | N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog |
| FR0802302 | 2008-04-24 | ||
| PCT/FR2009/000442 WO2009130422A2 (fr) | 2008-04-24 | 2009-04-16 | N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011519832A JP2011519832A (ja) | 2011-07-14 |
| JP2011519832A5 true JP2011519832A5 (enExample) | 2012-05-31 |
| JP5819188B2 JP5819188B2 (ja) | 2015-11-18 |
Family
ID=40085488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505549A Expired - Fee Related JP5819188B2 (ja) | 2008-04-24 | 2009-04-16 | ヘッジホッグタンパク質シグナル伝達経路のｎ−アシルチオウレア及びｎ−アシルウレア阻害物質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9073835B2 (enExample) |
| EP (1) | EP2291352B1 (enExample) |
| JP (1) | JP5819188B2 (enExample) |
| CA (1) | CA2722258C (enExample) |
| ES (1) | ES2651272T3 (enExample) |
| FR (1) | FR2930552B1 (enExample) |
| WO (1) | WO2009130422A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0619248Y2 (ja) | 1986-12-23 | 1994-05-18 | 旭硝子株式会社 | 読取センサ−ヘツド |
| EP2522341A1 (en) * | 2011-05-13 | 2012-11-14 | Tragex Pharma | Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers |
| FR2980477B1 (fr) * | 2011-09-23 | 2013-10-18 | Centre Nat Rech Scient | Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications |
| CN104220058A (zh) * | 2012-01-27 | 2014-12-17 | 国立大学法人富山大学 | 丝氨酸消旋酶抑制剂 |
| JP6045828B2 (ja) * | 2012-07-11 | 2016-12-14 | 千葉県 | 抗癌剤 |
| CN104529905B (zh) * | 2014-12-09 | 2017-10-31 | 沈阳药科大学 | N‑3‑苯并咪唑酰双胺类衍生物及其制备方法与应用 |
| US10548908B2 (en) | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
| WO2018211007A1 (en) * | 2017-05-18 | 2018-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
| CN112057443B (zh) * | 2019-10-12 | 2022-10-14 | 中国药科大学 | 苯磺酰胺类化合物的医药用途及其药物组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560770A (en) | 1983-02-09 | 1985-12-24 | Ciba-Geigy Corporation | Pesticidal compositions based on N-pyrrolylphenyl-N'-benzoylurea compounds |
| GB9413975D0 (en) * | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
| KR20010033470A (ko) * | 1997-12-23 | 2001-04-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 염증성 질병과 아테롬성경화증의 치료 또는 예방을 위한티오우레아 및 벤즈아미드 화합물, 조성물 및 방법 |
| AUPP873799A0 (en) | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
| DE10023430A1 (de) * | 2000-05-12 | 2001-11-15 | Bayer Ag | Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe |
| TWI236474B (en) * | 2001-04-03 | 2005-07-21 | Telik Inc | Antagonists of MCP-1 function and methods of use thereof |
| PE20021091A1 (es) * | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| EA007339B1 (ru) * | 2001-07-27 | 2006-08-25 | Кьюэрис, Инк. | Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ |
| US7262220B2 (en) * | 2002-07-11 | 2007-08-28 | Sanofi-Aventis Deutschland Gmbh | Urea- and urethane-substituted acylureas, process for their preparation and their use |
| JP4374428B2 (ja) * | 2002-07-11 | 2009-12-02 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 尿素置換されたおよびウレタン置換されたアシル尿素、それらの製造方法および医薬としてのそれらの使用方法 |
| AU2003249937A1 (en) * | 2002-07-12 | 2004-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| US7087761B2 (en) * | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
| US7179941B2 (en) * | 2003-01-23 | 2007-02-20 | Sanofi-Aventis Deutschland Gmbh | Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use |
| EP1695966A1 (en) * | 2003-07-22 | 2006-08-30 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| HRP20060100T3 (en) * | 2003-07-22 | 2007-03-31 | Arena Pharmaceuticals Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| FR2879598B1 (fr) * | 2004-12-17 | 2007-03-30 | Sod Conseils Rech Applic | Inhibiteurs de phosphatases cdc25 |
| US20080207760A1 (en) * | 2005-04-11 | 2008-08-28 | Achillion Pharmaceuticals, Inc. | Pharmaceutical Compositions For and Methods of Inhibiting Hcv |
| DE602007010664D1 (de) * | 2006-09-04 | 2010-12-30 | Univ Dundee | P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen |
| AU2007309279B2 (en) * | 2006-10-20 | 2011-03-24 | Irm Llc | Compositions and methods for modulating c-kit and PDGFR receptors |
-
2008
- 2008-04-24 FR FR0802302A patent/FR2930552B1/fr not_active Expired - Fee Related
-
2009
- 2009-04-16 JP JP2011505549A patent/JP5819188B2/ja not_active Expired - Fee Related
- 2009-04-16 US US12/988,975 patent/US9073835B2/en not_active Expired - Fee Related
- 2009-04-16 EP EP09733789.3A patent/EP2291352B1/fr not_active Not-in-force
- 2009-04-16 WO PCT/FR2009/000442 patent/WO2009130422A2/fr not_active Ceased
- 2009-04-16 CA CA2722258A patent/CA2722258C/fr not_active Expired - Fee Related
- 2009-04-16 ES ES09733789.3T patent/ES2651272T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519832A5 (enExample) | ||
| JP4422477B2 (ja) | ヘテロアリールスルホニル側鎖を有するアントラニル酸アミド、その製造方法、その医薬または診断助剤としての使用、およびこの化合物を含有する医薬製剤 | |
| JP4231295B2 (ja) | アントラニル酸アミド、その製造方法、抗不整脈剤としてのその使用、およびその医薬調製物 | |
| TWI333950B (en) | New benzimidazole derivatives | |
| JP5555868B2 (ja) | 新規なヒドロキサメート誘導体、その作製方法、及びこれを含有する薬学的組成物 | |
| JP2015502335A5 (enExample) | ||
| CA2690226A1 (en) | Novel malonic acid sulfonamide derivative and pharmaceutical use thereof | |
| WO2011145669A1 (ja) | アミド誘導体 | |
| CA2384974A1 (en) | Compounds and pharmaceutical compositions as cathepsin s inhibitors | |
| JP2004514707A (ja) | オルト−置換およびメタ−置換ビスアリール化合物、その製造法、医薬としてのその使用、並びにそれを含有する医薬製剤 | |
| JP4979583B2 (ja) | 新規のヒストンデアセチラーゼ阻害剤 | |
| JP2014502979A5 (enExample) | ||
| RU2014121394A (ru) | Двузамещенные соединения диамино-3,4-циклобутен-3-диона-1,2, приемлемые для лечения паталогий, опосредованных хемокинами | |
| JP2015514762A5 (enExample) | ||
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| JP2013508384A5 (enExample) | ||
| RU2012119247A (ru) | Модуляторы альфа-адренергических рецепторов | |
| CN105218532A (zh) | 苯并三氮唑类化合物、制备方法和其医药用途 | |
| JP2008545686A5 (enExample) | ||
| CN101759668A (zh) | 肉桂酰胺衍生物及其作为脑神经保护剂的应用 | |
| ES2715394T3 (es) | Nuevo antifúngico derivado de oxodihidropiridinacarbohidrazida | |
| CN102850236A (zh) | 新型苯甲酰胺类组蛋白去乙酰化酶抑制剂及其应用 | |
| JP5253174B2 (ja) | Ｎ−フェニルオキサミド酸誘導体 | |
| JP2004530650A5 (enExample) | ||
| CN103058959B (zh) | 一种n-(2-(4-甲基哌嗪-1-基)-5-甲酰苯基)酰胺类化合物及其应用 |